Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Teva launches generic Delzicol delayed-release capsules in the United States
May 10, 2019 Off

Teva launches generic Delzicol delayed-release capsules in the United States

By BusinessWire

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) todayannounced the launch of a generic version of Delzicol®1(mesalamine) delayed-release capsules, 400 mg, in the U.S.

Global oligonucleotide synthesis market could reach $2.9billion by 2024
May 10, 2019 Off

Global oligonucleotide synthesis market could reach $2.9billion by 2024

By BusinessWire

Global oligonucleotide synthesis market is expected to reach $2.9billion by 2024, at a CAGR of 10.5% during the forecast period of 2019to 2024.

May 10, 2019 Off

Greiner Bio-One Launches New MiniCollect® K2EDTA Capillary Tube into the Healthcare Market

By BusinessWire

MONROE, N.C.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/hospital?src=hash" target="_blank"gt;#hospitallt;/agt;–Greiner Bio-One is pleased to announce the launch of the newly redesigned MiniCollect® K2EDTA Capillary Collection…

FDA lists Sunovion’s, PsychoGenics’s SEP-363856 as breakthrough therapy for the treatment of schizophrenia
May 10, 2019 Off

FDA lists Sunovion’s, PsychoGenics’s SEP-363856 as breakthrough therapy for the treatment of schizophrenia

By BusinessWire

FDA) has granted Breakthrough Therapy Designation forSEP-363856, a novel agent for the treatment of people with schizophrenia.

North America contract research organization (CRO) market expected to reach $ 30.7B
May 10, 2019 Off

North America contract research organization (CRO) market expected to reach $ 30.7B

By BusinessWire

The North America contract research organization (CRO) market isexpected to reach US$ 30,730.1 Mn in 2025 from US$ 16,369.3 Mn in 2017.

Moderna with data which show vaccines targeting theH10N8 and H7N9 influenza viruses to be highly immunogenic andwell-tolerated in healthy adults
May 10, 2019 Off

Moderna with data which show vaccines targeting theH10N8 and H7N9 influenza viruses to be highly immunogenic andwell-tolerated in healthy adults

By BusinessWire

Published in the journal Vaccine, data show vaccines targeting theH10N8 and H7N9 influenza viruses to be highly immunogenic andwell-tolerated in healthy adults

Influenza Vaccines Market projected to exceed $6 Billion by 2025
May 10, 2019 Off

Influenza Vaccines Market projected to exceed $6 Billion by 2025

By BusinessWire

The global influenza vaccines market size is expected to surpass USD 6billion by 2025.

BioSpecifics Technologies ends quarter with $4.4 million
May 10, 2019 Off

BioSpecifics Technologies ends quarter with $4.4 million

By Dino Mustafić

BioSpecifics reported net income of $4.4 million for the first quarter 2019, compared to net income of $4.0 million, for the same period in 2018.

May 10, 2019 Off

BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®

By BusinessWire

ALAMEDA, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24BTX&src=ctag" target="_blank"gt;$BTXlt;/agt; lt;a href="https://twitter.com/hashtag/AMD?src=hash" target="_blank"gt;#AMDlt;/agt;–BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular…

Acceleron net loss for the first quartere 2019 $38.1M, R&D expenses $32.8
May 10, 2019 Off

Acceleron net loss for the first quartere 2019 $38.1M, R&D expenses $32.8

By BusinessWire

Acceleron net loss for the first quartere 2019 $38.1M, R&D expenses $32.8

Posts pagination

Previous 1 … 3,202 3,203 3,204 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine